Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended-Release Capsules (US RLD - ADDERALL XR®), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 50 mg.
The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADH) which is a brain disorder characterized by an ongoing pattern of inattention and, or hyperactivity-impulsivity that interferes with functioning or development. It will be manufactured at Nesher Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.
The group now has 269 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.231 as compared to the previous close of Rs. 240.6. The total number of shares traded during the day was 162721 in over 1045 trades.
The stock hit an intraday high of Rs. 242.95 and intraday low of 229.2. The net turnover during the day was Rs. 38073028.